2.1 Million Women: Breast Cancer Treatment Developed By This Company
Plus Therapeutics Gains FDA Orphan Drug Designation for Groundbreaking Breast Cancer Treatment.
In a significant stride forward for the medical community and patients alike, Plus Therapeutics, a clinical-stage pharmaceutical company, has recently received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA). The designation is for their innovative Bmeda-chelated Rhenium-186 Nanoliposomes, which are being developed for the treatment of breast cancer with leptomeningeal metastases.
Leptomeningeal metastases, a condition where cancer cells spread to the membranes surrounding the brain and spinal cord, is a particularly aggressive form of breast cancer and notoriously difficult to treat, making this development by Plus Therapeutics especially groundbreaking.
The Orphan Drug Designation by the FDA is granted to drugs and biologics that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the U.S. This designation provides certain benefits, including tax credits for qualified clinical trials costs, exemptions from certain FDA application fees, and seven years of market exclusivity upon regulatory product approval.
Dr. Marc Hedrick, President and Chief Executive Officer of Plus Therapeutics, expressed his company's enthusiasm about the designation. "We are extremely proud of our team’s work and grateful to the FDA for recognizing the potential of our novel investigational drug," he said. "We remain dedicated to advancing our clinical development program and bringing this potentially life-saving treatment to patients as quickly as possible."
The Bmeda-chelated Rhenium-186 Nanoliposomes treatment is a testament to Plus Therapeutics' commitment to developing innovative treatments for hard-to-treat cancers. The company, renowned in the medical community for its pioneering work, is headquartered in Austin, Texas, and focuses on the discovery and development of innovative treatments for patients battling cancer.
This development not only represents a significant potential breakthrough in the treatment of breast cancer with leptomeningeal metastases but also brings renewed hope to patients and their families. The progress made by Plus Therapeutics underscores the importance of continued investment in research and development in the fight against cancer.
However, it's important to remember that while these developments are promising, the drug is still in the experimental stage and has not yet been approved for public use.
Disclaimer: This article is for informational purposes only and is not intended to provide medical advice, which should be obtained from a medical professional. Any information on products or treatments discussed herein is provided for discussion and does not constitute endorsement or recommendation by this website.
Disclosure: This post includes no affiliate links. The author/website does not benefit from your engagement with any of the links included in this article.
As an investor it's important to stay updated with major news. Get real-time alerts by creating an account here.
Sources: